NYSE · COR
Healthcare · Medical - Distribution
$308.78
Down-$0.63 (-0.20%)
Updated Sep 20, 2026, 12:36 AM
SID Score
5.1/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
COR closed at $308.78 after 19 trading sessions, down 4.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $307.42 | $311.81 | $304.45 | $308.78 | 3.34M |
| Sep 17, 2026 | $318.36 | $319.765 | $309.24 | $309.41 | 1.1M |
| Sep 16, 2026 | $321.83 | $323.98 | $317.97 | $318.50 | 931.14K |
| Sep 15, 2026 | $324.98 | $325.875 | $318.08 | $323.29 | 913.5K |
| Sep 14, 2026 | $325.64 | $327.79 | $322.46 | $326.23 | 1.06M |
| Sep 11, 2026 | $323.99 | $325.125 | $317.96 | $321.57 | 844.06K |
| Sep 10, 2026 | $326.34 | $327.90 | $320.91 | $320.95 | 1.35M |
| Sep 9, 2026 | $322.24 | $326.99 | $321.915 | $323.32 | 1.22M |
| Sep 8, 2026 | $327.55 | $330.00 | $323.05 | $324.69 | 2.2M |
| Sep 4, 2026 | $333.48 | $336.01 | $330.201 | $330.95 | 1.03M |
| Sep 3, 2026 | $337.90 | $338.71 | $334.87 | $337.22 | 1.09M |
| Sep 2, 2026 | $330.62 | $337.91 | $330.62 | $336.36 | 1.4M |
| Sep 1, 2026 | $325.97 | $331.65 | $325.92 | $330.97 | 1.52M |
| Aug 31, 2026 | $321.11 | $326.57 | $319.04 | $323.60 | 1.39M |
| Aug 28, 2026 | $322.30 | $323.74 | $320.39 | $322.03 | 628.86K |
| Aug 27, 2026 | $324.35 | $324.68 | $320.465 | $321.23 | 1.07M |
| Aug 26, 2026 | $328.39 | $330.995 | $326.30 | $327.79 | 841.57K |
| Aug 25, 2026 | $322.68 | $328.51 | $321.43 | $328.06 | 1.11M |
| Aug 24, 2026 | $317.76 | $324.58 | $317.65 | $323.77 | 760.4K |
The latest Smart Investors Daily articles mentioning COR.
COR research
Company profile and research snapshot.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | RBC Capital | Sector Perform | — |
| Aug 19, 2026 | RBC Capital | Sector Perform | — |
| Aug 11, 2026 | Wells Fargo | Overweight | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Morgan Stanley | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 19, 2026
On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion […]
Yahoo · Sep 16, 2026
Cencora Global Chief Data and Information Officer Pawan Verma spoke with WSJ Leadership Institute President Alan Murray at the WSJLI Technology Council Summit about how AI is being used in healthcare to speed access to treatment. Verma described a retinal oncology use case in which doctors analyze large volumes of imaging data to determine treatment, saying Cencora is helping cut a decision process that can take 30 to 90 days roughly in half.
SeekingAlpha · Sep 15, 2026
Cencora, Inc. (COR) 2026 Global Healthcare Conference September 15, 2026 3:10 PM EDTCompany ParticipantsEva Boratto - Executive VP & CFORobert Mauch -...
Yahoo · Sep 15, 2026
A panel of CIOs from Indeed, New York Life and Cencora discuss the risks and advantages of enterprise AI, including operational efficiency, financial waste and the need to implement “control towers” for human oversight of consequential decisions.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COR.
